Paratek Announces Public Offering of Common Stock
January 17 2018 - 4:06PM
Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical
company focused on the development and commercialization of
innovative therapies based upon its expertise in novel tetracycline
chemistry, today announced that it has commenced a registered
underwritten public offering of $50.0 million of its shares of
common stock. In addition, Paratek has granted the underwriter a
30-day option to purchase up to an additional $7.5 million of its
shares of common stock. All of the shares to be sold in the
offering are to be sold by Paratek.
BTIG, LLC is acting as sole book-running manager for the
offering.
A shelf registration statement on Form S-3 relating to the
public offering of the shares of common stock described above was
declared effective by the Securities and Exchange Commission (SEC)
on October 29, 2015. Before you invest, you should read the
prospectus in the registration statement and related preliminary
prospectus supplement that Paratek will file with the SEC for more
complete information about Paratek and this offering. An electronic
copy of the preliminary prospectus supplement and accompanying
prospectus relating to the offering will be available on the
website of the SEC at www.sec.gov. Copies of the preliminary
prospectus supplement, when available, and the accompanying
prospectus relating to the offering may be obtained by contacting
BTIG, LLC, at 825 Third Avenue, 6th Floor, New York, NY, 10022, or
by telephone at (212) 593-7555 or by e-mail at
equitycapitalmarkets@btig.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or other jurisdiction.
About Paratek Pharmaceuticals, Inc.Paratek
Pharmaceuticals, Inc. is a clinical stage biopharmaceutical
company focused on the development and commercialization of
innovative therapeutics based upon tetracycline chemistry. Paratek
has used its expertise in biology and tetracycline chemistry to
create chemically diverse and biologically distinct small molecules
derived from the minocycline core structure. Paratek’s two
lead product candidates are the antibacterials, omadacycline and
sarecycline.
CONTACTS:
Media Relations: |
Investor Relations: |
Michael Lampe |
Hans
Vitzthum |
(484)
575-5040 |
LifeSci Advisors, LLC. |
michael@scientpr.com |
212-915-2568 |
Paratek Pharmaceuticals (NASDAQ:PRTK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Paratek Pharmaceuticals (NASDAQ:PRTK)
Historical Stock Chart
From Sep 2023 to Sep 2024